iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharma gets USFDA approval for generic Mesalamine capsules

13 May 2022 , 08:59 AM

The generic product approval is based on Pentasa extended release capsules, 500 mg as a reference product, Sun Pharmaceutical Industries said in a statement. As per March 2022 IQVIA Health data, Pentasa extended release capsules, 500mg had annualized sales of approximately $213 million in USA. Sun Pharma is the worlds fourth largest specialty generic pharmaceutical company and Indias top pharmaceutical company. The companys board will consider Q4 results on 30 May 2022. The companys consolidated net profit grew 11.13% to Rs 2,058.80 crore on 11.61% rise in total revenue from operations to Rs 9,863.06 crore in Q3 December 2021 over Q3 December 2020. Shares of Sun Pharma fell 0.64% to settle at Rs 850.15 on Thursday. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.